Darolutamide news

All news on Darolutamide (also known as Nubeqa): plants, production capacities, investments and involved companies.

2 February 2026

Johnson & Johnson: ERLEADA® reduces death risk by 51% in mCSPC patients vs. darolutamide

Real-world study shows ERLEADA® offers significant survival benefits for mCSPC patients without docetaxel, supporting its use as a standard treatment.
21 July 2025

EU Approves Bayer's Nubeqa for Advanced Prostate Cancer

EU approves darolutamide with ADT for mHSPC, based on ARANOTE trial. Offers treatment flexibility with or without chemotherapy, enhancing patient care.

Who will be producing Darolutamide in the future?

Find out with chemXplore Analytics